[Tyrosine kinase inhibitors. An approach to pathogenesis-oriented tumor therapy].
Alves
F
F
Abteilung Hämatologie und Onkologie, Universitätsklinik Göttingen.
Hiddemann
W
W
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000503:physiopathology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D011505:Protein-Tyrosine Kinases
Tyrosinkinaseinhibitoren. Ein Ansatz zur Pathogeneseorientierten Tumortherapie.